Los países de la UE aúnan fuerzas contra el ‛exorbitante’ precio de un fármaco para tratar la hepatitis C

Noticias

Los países de la UE aúnan fuerzas contra el ‛exorbitante’ precio de un fármaco para tratar la hepatitis C

23 julio 2014

Francia ha declarado que ha sumado fuerzas con otros 13 países europeos para negociar un precio más bajo para un prometedor fármaco contra la hepatitis C que ha suscitado polémicas por su astronómico precio. Más información, en inglés, está disponible abajo.

Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas.

France said Thursday it has joined forces with 13 other European countries to negotiate a lower price for a promising new hepatitis C drug that has drawn controversy for its astronomical cost.

Sovaldi, made by US pharmaceutical firm Gilead Sciences, has shown huge potential at helping cure the liver disease but its price -- more than 50,000 euros ($68,000) for a 12-week course of treatment -- has health authorities concerned.

"If we accept such a high price, firstly we won't be able to treat everyone and we will also be creating a risk for our social security system, which means for other patients," French Health Minister Marisol Touraine said Thursday.

She told BFMTV that Sovaldi would cost the country's already heavily-indebted welfare system billions of euros. "So I launched an initiative... to mobilise all European countries and make sure we join forces to weigh on price negotiations with this US laboratory.

"For the first time, 14 European countries have made a commitment together. We will therefore negotiate country by country as that's how it's done, but we will exchange information and discuss things between European countries."

Read the full article.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.